Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy
Background Narrowband UVB (NB-UVB) phototherapy is considered an accepted therapy for vitiligo. Objective We sought to estimate the effectiveness of NB-UVB in patients with vitiligo, identify predictive factors of response, and assess the stability of NB-UVB–induced repigmentation. Methods In all, 7...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology 2007-02, Vol.56 (2), p.274-278 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 278 |
|---|---|
| container_issue | 2 |
| container_start_page | 274 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 56 |
| creator | Nicolaidou, Electra, MD Antoniou, Christina, MD Stratigos, Alexander J., MD Stefanaki, Christina, MD Katsambas, Andreas D., MD |
| description | Background Narrowband UVB (NB-UVB) phototherapy is considered an accepted therapy for vitiligo. Objective We sought to estimate the effectiveness of NB-UVB in patients with vitiligo, identify predictive factors of response, and assess the stability of NB-UVB–induced repigmentation. Methods In all, 70 patients with vitiligo were treated twice weekly with NB-UVB. Results Cosmetically acceptable (>75%) repigmentation was achieved in 34.4% of patients with lesions on the face and in 7.4% of patients with lesions on the body. Patients with phototypes III to V had a greater chance to achieve greater than 75% repigmentation on the face. Patients who responded in the first month of treatment were more likely to achieve better repigmentation rates. Repigmentation was stable in 14.3% of patients 4 years after cessation of treatment. Limitations The study was uncontrolled. Treatment frequency was twice weekly. These results may not be representative of different treatment regimens. Conclusion Patients with vitiligo who have lesions on the face, darker phototypes, and early response to treatment have a greater chance to achieve satisfactory repigmentation after NB-UVB phototherapy. |
| doi_str_mv | 10.1016/j.jaad.2006.09.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68921477</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0190962206025291</els_id><sourcerecordid>68921477</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-cbcdfa165cfe3d31d695de079f5d8f3559bbc5dbc68cb9179e2e7105c212cd303</originalsourceid><addsrcrecordid>eNp9kkGL1DAYhoso7rj6BzxILnra1i9pmzYggi67Kix40PUa0uTLTmqnqUm6w4A_fltmYMGDp0B43jfh-b4se02hoED5-77olTIFA-AFiAKgepJtKIgm503bPM02QAXkgjN2lr2IsQcAUZXN8-yMNoxVJReb7O-VtU4rfbggU0DjdPIhEm9JwDj5MeIFUaMhgx_v8oRhR6wfBr_P54m4kUwqORxTJHuXtuTeJTe4O09SQJXQHG9HFYLfd2vL7a_PZNr65NMWg5oOL7NnVg0RX53O8-z2-urn5df85vuXb5efbnJdlSLlutPGKsprbbE0JTVc1AahEbY2rS3rWnSdrk2neas7QRuBDBsKtWaUaVNCeZ69O_ZOwf-ZMSa5c1HjMKgR_RwlbwWjVdMsIDuCOvgYA1o5BbdT4SApyNW57OXqXK7OJQi5OF9Cb07tc7dD8xg5SV6AtydARa0GG9SoXXzkWsFbXq-vfzhyuLi4dxhk1ItevYwloE7SePf_f3z8J64HNy7DHX7jAWPv5zAuliWVkUmQP9btWJcDOLCaCVo-AFGCtzo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68921477</pqid></control><display><type>article</type><title>Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Nicolaidou, Electra, MD ; Antoniou, Christina, MD ; Stratigos, Alexander J., MD ; Stefanaki, Christina, MD ; Katsambas, Andreas D., MD</creator><creatorcontrib>Nicolaidou, Electra, MD ; Antoniou, Christina, MD ; Stratigos, Alexander J., MD ; Stefanaki, Christina, MD ; Katsambas, Andreas D., MD</creatorcontrib><description>Background Narrowband UVB (NB-UVB) phototherapy is considered an accepted therapy for vitiligo. Objective We sought to estimate the effectiveness of NB-UVB in patients with vitiligo, identify predictive factors of response, and assess the stability of NB-UVB–induced repigmentation. Methods In all, 70 patients with vitiligo were treated twice weekly with NB-UVB. Results Cosmetically acceptable (>75%) repigmentation was achieved in 34.4% of patients with lesions on the face and in 7.4% of patients with lesions on the body. Patients with phototypes III to V had a greater chance to achieve greater than 75% repigmentation on the face. Patients who responded in the first month of treatment were more likely to achieve better repigmentation rates. Repigmentation was stable in 14.3% of patients 4 years after cessation of treatment. Limitations The study was uncontrolled. Treatment frequency was twice weekly. These results may not be representative of different treatment regimens. Conclusion Patients with vitiligo who have lesions on the face, darker phototypes, and early response to treatment have a greater chance to achieve satisfactory repigmentation after NB-UVB phototherapy.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2006.09.004</identifier><identifier>PMID: 17224369</identifier><identifier>CODEN: JAADDB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Child ; Dermatology ; Female ; Humans ; Logistic Models ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Phototherapy - methods ; Pigmentary diseases of the skin ; Treatment Outcome ; Ultraviolet Rays ; Vitiligo - therapy</subject><ispartof>Journal of the American Academy of Dermatology, 2007-02, Vol.56 (2), p.274-278</ispartof><rights>American Academy of Dermatology, Inc.</rights><rights>2007 American Academy of Dermatology, Inc.</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-cbcdfa165cfe3d31d695de079f5d8f3559bbc5dbc68cb9179e2e7105c212cd303</citedby><cites>FETCH-LOGICAL-c439t-cbcdfa165cfe3d31d695de079f5d8f3559bbc5dbc68cb9179e2e7105c212cd303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0190962206025291$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18968657$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17224369$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nicolaidou, Electra, MD</creatorcontrib><creatorcontrib>Antoniou, Christina, MD</creatorcontrib><creatorcontrib>Stratigos, Alexander J., MD</creatorcontrib><creatorcontrib>Stefanaki, Christina, MD</creatorcontrib><creatorcontrib>Katsambas, Andreas D., MD</creatorcontrib><title>Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>Background Narrowband UVB (NB-UVB) phototherapy is considered an accepted therapy for vitiligo. Objective We sought to estimate the effectiveness of NB-UVB in patients with vitiligo, identify predictive factors of response, and assess the stability of NB-UVB–induced repigmentation. Methods In all, 70 patients with vitiligo were treated twice weekly with NB-UVB. Results Cosmetically acceptable (>75%) repigmentation was achieved in 34.4% of patients with lesions on the face and in 7.4% of patients with lesions on the body. Patients with phototypes III to V had a greater chance to achieve greater than 75% repigmentation on the face. Patients who responded in the first month of treatment were more likely to achieve better repigmentation rates. Repigmentation was stable in 14.3% of patients 4 years after cessation of treatment. Limitations The study was uncontrolled. Treatment frequency was twice weekly. These results may not be representative of different treatment regimens. Conclusion Patients with vitiligo who have lesions on the face, darker phototypes, and early response to treatment have a greater chance to achieve satisfactory repigmentation after NB-UVB phototherapy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Dermatology</subject><subject>Female</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Phototherapy - methods</subject><subject>Pigmentary diseases of the skin</subject><subject>Treatment Outcome</subject><subject>Ultraviolet Rays</subject><subject>Vitiligo - therapy</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kkGL1DAYhoso7rj6BzxILnra1i9pmzYggi67Kix40PUa0uTLTmqnqUm6w4A_fltmYMGDp0B43jfh-b4se02hoED5-77olTIFA-AFiAKgepJtKIgm503bPM02QAXkgjN2lr2IsQcAUZXN8-yMNoxVJReb7O-VtU4rfbggU0DjdPIhEm9JwDj5MeIFUaMhgx_v8oRhR6wfBr_P54m4kUwqORxTJHuXtuTeJTe4O09SQJXQHG9HFYLfd2vL7a_PZNr65NMWg5oOL7NnVg0RX53O8-z2-urn5df85vuXb5efbnJdlSLlutPGKsprbbE0JTVc1AahEbY2rS3rWnSdrk2neas7QRuBDBsKtWaUaVNCeZ69O_ZOwf-ZMSa5c1HjMKgR_RwlbwWjVdMsIDuCOvgYA1o5BbdT4SApyNW57OXqXK7OJQi5OF9Cb07tc7dD8xg5SV6AtydARa0GG9SoXXzkWsFbXq-vfzhyuLi4dxhk1ItevYwloE7SePf_f3z8J64HNy7DHX7jAWPv5zAuliWVkUmQP9btWJcDOLCaCVo-AFGCtzo</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>Nicolaidou, Electra, MD</creator><creator>Antoniou, Christina, MD</creator><creator>Stratigos, Alexander J., MD</creator><creator>Stefanaki, Christina, MD</creator><creator>Katsambas, Andreas D., MD</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070201</creationdate><title>Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy</title><author>Nicolaidou, Electra, MD ; Antoniou, Christina, MD ; Stratigos, Alexander J., MD ; Stefanaki, Christina, MD ; Katsambas, Andreas D., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-cbcdfa165cfe3d31d695de079f5d8f3559bbc5dbc68cb9179e2e7105c212cd303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Dermatology</topic><topic>Female</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Phototherapy - methods</topic><topic>Pigmentary diseases of the skin</topic><topic>Treatment Outcome</topic><topic>Ultraviolet Rays</topic><topic>Vitiligo - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nicolaidou, Electra, MD</creatorcontrib><creatorcontrib>Antoniou, Christina, MD</creatorcontrib><creatorcontrib>Stratigos, Alexander J., MD</creatorcontrib><creatorcontrib>Stefanaki, Christina, MD</creatorcontrib><creatorcontrib>Katsambas, Andreas D., MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nicolaidou, Electra, MD</au><au>Antoniou, Christina, MD</au><au>Stratigos, Alexander J., MD</au><au>Stefanaki, Christina, MD</au><au>Katsambas, Andreas D., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2007-02-01</date><risdate>2007</risdate><volume>56</volume><issue>2</issue><spage>274</spage><epage>278</epage><pages>274-278</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><coden>JAADDB</coden><abstract>Background Narrowband UVB (NB-UVB) phototherapy is considered an accepted therapy for vitiligo. Objective We sought to estimate the effectiveness of NB-UVB in patients with vitiligo, identify predictive factors of response, and assess the stability of NB-UVB–induced repigmentation. Methods In all, 70 patients with vitiligo were treated twice weekly with NB-UVB. Results Cosmetically acceptable (>75%) repigmentation was achieved in 34.4% of patients with lesions on the face and in 7.4% of patients with lesions on the body. Patients with phototypes III to V had a greater chance to achieve greater than 75% repigmentation on the face. Patients who responded in the first month of treatment were more likely to achieve better repigmentation rates. Repigmentation was stable in 14.3% of patients 4 years after cessation of treatment. Limitations The study was uncontrolled. Treatment frequency was twice weekly. These results may not be representative of different treatment regimens. Conclusion Patients with vitiligo who have lesions on the face, darker phototypes, and early response to treatment have a greater chance to achieve satisfactory repigmentation after NB-UVB phototherapy.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>17224369</pmid><doi>10.1016/j.jaad.2006.09.004</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 2007-02, Vol.56 (2), p.274-278 |
| issn | 0190-9622 1097-6787 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68921477 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adult Aged Biological and medical sciences Child Dermatology Female Humans Logistic Models Male Medical sciences Middle Aged Multivariate Analysis Phototherapy - methods Pigmentary diseases of the skin Treatment Outcome Ultraviolet Rays Vitiligo - therapy |
| title | Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T09%3A48%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy,%20predictors%20of%20response,%20and%20long-term%20follow-up%20in%20patients%20with%20vitiligo%20treated%20with%20narrowband%20UVB%20phototherapy&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Nicolaidou,%20Electra,%20MD&rft.date=2007-02-01&rft.volume=56&rft.issue=2&rft.spage=274&rft.epage=278&rft.pages=274-278&rft.issn=0190-9622&rft.eissn=1097-6787&rft.coden=JAADDB&rft_id=info:doi/10.1016/j.jaad.2006.09.004&rft_dat=%3Cproquest_cross%3E68921477%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68921477&rft_id=info:pmid/17224369&rft_els_id=1_s2_0_S0190962206025291&rfr_iscdi=true |